https://vettaintech.com/research/the-regulatory-fast-lane-how-fda-s-streamlined-pathways-are-unlocking-in-vivo-gene-editing-s-multi-trillion-dollar-promise-1785535512078 Vetta Investments en 2026-07-31T22:05:12.000Z The Regulatory Fast Lane: How FDA's Streamlined Pathways Are Unlocking In Vivo Gene Editing's Multi-Trillion-Dollar Promise FDA streamlined pathways, in vivo gene editing, gene editing market 2040, sickle cell disease market, biotech investment opportunities, accelerated regulatory review, gene therapy development, Vetta Framework, CRISPR therapies, personalized medicine FDA